Table 2.
Single nucleotide polymorphisms (SNPs) associated with colorectal cancer (CRC) risk in primary selenium pathway 1 (selenium and selenoprotein transport, biosynthesis and metabolism) with raw P-values < 0.01 in at least one genetic model prior to multiple testing adjustment, the EPIC study, 1992–2003.
| Gene/SNP/Genotype | CRC | Control | OR (95% CI) | P | PBH+ |
|---|---|---|---|---|---|
| GPX1/rs17080528 | |||||
| GG | 700 | 620 | 1.00 (ref) | 0.010 | 0.703 |
| GA | 580 | 636 | 0.81 (0.69,0.95) | ||
| AA | 131 | 154 | 0.75 (0.58,0.97) | ||
| Additive * | 1411 | 1410 | 0.84 (0.75,0.95) | 0.003 | 0.554 |
| Dominant (GA + AA vs. GG) | 1411 | 1410 | 0.80 (0.69,0.92) | 0.003 | 0.534 |
| Recessive (AA vs. GG + GA) | 1411 | 1410 | 0.83 (0.65,1.06) | 0.137 | 0.854 |
| SELENOM/rs11705137 | |||||
| AA | 367 | 346 | 1.00 (ref) | 0.024 | 0.753 |
| AG | 631 | 648 | 0.91 (0.75,1.09) | ||
| GG | 288 | 359 | 0.74 (0.60,0.92) | ||
| Additive * | 1286 | 1353 | 0.86 (0.78,0.96) | 0.008 | 0.684 |
| Dominant (AG + GG vs. AA) | 1286 | 1353 | 0.85 (0.71,1.01) | 0.064 | 0.815 |
| Recessive (GG vs. AA + AG) | 1286 | 1353 | 0.79 (0.66,0.95) | 0.012 | 0.710 |
| SELENON/rs4659382 | |||||
| GG | 783 | 713 | 1.00 (ref) | 0.019 | 0.747 |
| GC | 509 | 573 | 0.80 (0.69,0.94) | ||
| CC | 96 | 107 | 0.82 (0.61,1.10) | ||
| Additive * | 1388 | 1393 | 0.86 (0.76,0.97) | 0.011 | 0.710 |
| Dominant (GC + CC vs. GG) | 1388 | 1393 | 0.81 (0.69,0.94) | 0.005 | 0.625 |
| Recessive (CC vs. GG + GC) | 1388 | 1393 | 0.90 (0.67,1.20) | 0.455 | 0.954 |
| SEPHS1/rs2275129 | |||||
| GG | 361 | 423 | 1.00 (ref) | 0.032 | 0.780 |
| GC | 726 | 690 | 1.23 (1.03,1.47) | ||
| CC | 321 | 295 | 1.28 (1.04,1.58) | ||
| Additive * | 1408 | 1408 | 1.14 (1.02,1.26) | 0.017 | 0.747 |
| Dominant (GC + CC vs. GG) | 1408 | 1408 | 1.25 (1.05,1.47) | 0.010 | 0.697 |
| Recessive (CC vs. GG + GC) | 1408 | 1408 | 1.12 (0.94,1.34) | 0.217 | 0.885 |
| TXNRD1/rs11111979 ^ | |||||
| GG | 395 | 429 | 1.00 (ref) | 0.015 | 0.745 |
| GC | 627 | 680 | 1.00 (0.84,1.20) | ||
| CC | 279 | 230 | 1.34 (1.07,1.67) | ||
| Additive * | 1301 | 1339 | 1.14 (1.02,1.27) | 0.022 | 0.749 |
| Dominant (GC + CC vs. GG) | 1301 | 1339 | 1.09 (0.92,1.28) | 0.315 | 0.932 |
| Recessive (CC vs. GG + GC) | 1301 | 1339 | 1.33 (1.10,1.62) | 0.004 | 0.566 |
+ = After Benjamini–Hochberg (BH) multiple testing correction; * = Additive models impose a structure in which each additional copy of the variant allele increases the response (log odds ratio) by the same amount; ^ = TXNRD1 rs11111979 was borderline significant after adjustment for correlated tests (PACT = 0.10). EPIC = European Prospective Investigation into Cancer and Nutrition.